Evidence map›Paper›PMID 39525480›Full record

ArticleF1000Research2022

Does the impact of medical publications vary by disease indication and publication type? An exploration using a novel, value-based, publication metric framework: the EMPIRE Index.

Tomas Rees, Avishek Pal

Abstract read
In one paragraph

Article in F1000Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Tomas ReesOxford PharmaGenesis, Oxford, Oxfordshire, OX13 5QJ, UK.ORCID 0000-0003-0221-0098
Avishek PalNovartis Pharma AG, Basel, Switzerland.ORCID 0000-0002-2213-3336

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The EMPIRE (EMpirical Publication Impact and Reach Evaluation) Index is a value-based, multi-component metric framework to assess the impact of medical publications in terms of relevance to different stakeholders. It comprises three component scores (social, scholarly and societal impact), each incorporating related altmetrics that indicate a different aspect of engagement with the publication. Here, we present an exploratory investigation of whether publication types or disease indications influence EMPIRE Index scores. Methods: Article-level metrics were extracted and EMPIRE Index scores were calculated for 5825 journal articles published from 1 May 2017 to 1 May 2018, representing 12 disease indications (chosen to reflect a wide variety of common and rare diseases with a variety of aetiologies) and five publication types. Results: There were significant differences in scores between article types and disease indications. Median (95% CI) social and scholarly impact scores ranged from 1.2 (0.3-1.6) to 4.8 (3.1-6.6), respectively, for phase 3 clinical trials, and from 0.3 (0.3-0.4) to 2.3 (1.9-2.6), respectively, for observational studies. Social and scholarly impact scores were highest for multiple sclerosis publications and lowest for non-small cell lung cancer publications. Systematic reviews achieved greater impact than regular reviews. Median trends in the social impact of different disease areas matched the level of public interest as assessed through Google search interest. Although most articles did not register societal impact, mean societal impact scores were highest for migraine publications. Conclusions: The EMPIRE Index successfully identified differences in impact by disease area and publication type, which supports the notion that the impact of each publication needs to be evaluated in the context of these factors, and potentially others. These findings should be considered when using the EMPIRE Index to assess publication impact.

Indexed as

PublicationsBibliometricsHumansJournal Impact FactorPeriodicals as TopicPublishingAltmetricsbibliometricspublication impact

Identifiers

PMID39525480
PMCPMC11549536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.